All In Biotech

Investigational drug · Phase 3

BGM0504

Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type 2 Diabetes (T2DM), Overweight or Obese Participants Without Diabetes, Obesity.

Phase 3

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

5

3 still active

All registered trials

17

Any phase or sponsor naming "BGM0504"

First trial start

2024

Oct 29, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "BGM0504", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Type 2 Diabetes (T2DM)
  • Overweight or Obese Participants Without Diabetes
  • Obesity
  • Overweight or Obesity

Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "BGM0504" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 4 on PubMed

Also in development for Type 2 Diabetes (T2DM)

  • ObicetrapibPhase 37 trials

    NewAmsterdam Pharma · Lipidemia, Preclinical Alzheimer's Disease, Antioxidant Absorption

  • ezetimibe FDCPhase 32 trials

    NewAmsterdam Pharma · Lipidemia, Coronary Artery Disease, Plaque, Atherosclerotic

  • F027Phase 31 trial

    Shandong New Time Pharmaceutical Co., LTD · Type 2 Diabetes (T2DM)

  • GZR101-80Phase 21 trial

    Gan & Lee Pharmaceuticals. · Type 2 Diabetes (T2DM)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.